NEXT-GENERATION METABOLIC SCIENCE

Retatrutide introduces a triple-hormone approach to weight loss.

The “Triple-G” mechanism combines GLP-1, GIP, and glucagon activity to influence appetite, insulin response, and energy expenditure in a single once-weekly treatment strategy.

Important note: As of early 2026, retatrutide is primarily in late-stage clinical trials and may not yet be available for general prescription in all regions.

3 Receptor Targets

GLP-1

GIP

Glucagon

Appetite + insulin + thermogenesis

Potential body weight reduction exceeding 24% over 48 weeks

Designed to support metabolic rate during weight loss

Preliminary data suggests reduction in liver fat

Built for robust glycemic support and insulin response

How it works

The Triple-G mechanism.

Retatrutide works by mimicking three naturally occurring hormones in the body, creating a synergistic effect on hunger and energy expenditure.

GLP-1

Glucagon-like peptide-1 slows gastric emptying and signals the brain to feel full.

GIP

Glucose-dependent insulinotropic polypeptide improves insulin sensitivity and helps break down fat.

Glucagon

Increases energy expenditure, supports calorie burning, and targets fat stored in the liver.

Why it matters

Metabolic benefits beyond appetite alone.

Unprecedented weight loss

In clinical trials, retatrutide has shown the potential for body weight reductions exceeding 24% over 48 weeks.

Metabolic synergy

By adding the glucagon receptor, it specifically addresses metabolic rate, which can often slow down during traditional dieting.

Liver health

Preliminary data suggests a significant impact on reducing liver fat, making it a primary candidate for treating fatty liver disease, including MASLD and MASH.

Glycemic control

Provides robust support for blood sugar regulation and insulin response.

Comparative overview

From one receptor target to three.

Retatrutide extends the progression from semaglutide to tirzepatide by adding glucagon activity to appetite and insulin pathways.

Feature Semaglutide Tirzepatide Retatrutide

Receptor targets 1 (GLP-1) 2 (GLP-1 + GIP) 3 (GLP-1 + GIP + Glucagon)

Primary focus Appetite Appetite + insulin Appetite + insulin + thermogenesis

Average weight loss ~15% ~21% ~24%+

Usage & administration

Once weekly, introduced gradually.

Retatrutide is typically administered via a once-weekly subcutaneous injection. Like its predecessors, it is usually introduced at a low titration dose to allow the digestive system to adapt.

This gradual ramp can help minimize common side effects such as nausea or gastrointestinal discomfort.

Important note

Retatrutide should only be used under the strict supervision of a healthcare provider.